毓金方治疗痰湿蕴肺型中晚期非小细胞肺癌的临床疗效观察

发布时间：2018-11-20 06:20

【摘要】：目的：通过对毓金方治疗痰湿蕴肺型中晚期非小细胞肺癌的临床疗效的观察,证明毓金方在治疗痰湿蕴肺型中晚期非小细胞肺癌有很好的疗效。方法：收集2014年6月到2015年12月黑龙江中医药大学附属一院门诊及住院中晚期非小细胞肺癌的患者60例,随机分为两组,每组30人。其诊断均经组织病理学或者细胞学检查证实。最后完成疗程及病例完整者只有59例,其中治疗组30例和对照组29例。治疗组：毓金方+康莱特注射液治疗,毓金方连服,康莱特注射液,连续静脉滴注治疗14天,休息2周,28天为一周期；对照组：康莱特注射液,连续静脉滴注治疗14天,休息2周,28天为一周期；治疗组对照组均连续治疗三周期。观察和比较两组治疗前后近期疗效、肿瘤标志物CEA, ECOG,中医证候评分的变化。结果：1.以RECIST为标准的近期疗效观察治疗组的疾病控制率是86.67%,对照组疾病控制率为65.52%,组间比较p0.05有统计学意义,表明治疗组优于对照组。2.两组组内比较肿瘤标志物CEA表达治疗前后有显著性差异p0.05,有统计学意义；两组组间比较治疗后肿瘤标志物CEA表达有显著性差异p0.05,有统计学意义,表明治疗组优于对照组。3.两组组内比较ECOG评分治疗前与治疗后有显著性差异p0.05,有统计学意义；两组组间比较治疗后ECOG评分有显著性差异p0.05,有统计学意义,表明治疗组优于对照组。4.两组组内比较中医症候积分治疗前与治疗后有显著性差异p0.05,有统计学意义；两组组间比较疗后中医症候积分有显著性差异p0.05,有统计学意义,表明治疗组优于对照组。结论：1.毓金方能有效提高疾病控制率；2.毓金方能显著降低肿瘤标志物CEA的水平；3.毓金方能显著改善体力状态,降低ECOG评分；4.毓金方能显著改善临床症状,降低中医症候积分。
[Abstract]:Objective: to observe the clinical effect of Yujin recipe in treating middle and late stage non small cell lung cancer of phlegm dampness accumulation lung type, and to prove that Yujin prescription has good curative effect on middle and late non small cell lung cancer of phlegm dampness accumulation lung type. Methods: from June 2014 to December 2015, 60 patients with advanced non-small cell lung cancer (NSCLC) were randomly divided into two groups, 30 in each group. The diagnosis was confirmed by histopathology or cytology. There were only 59 cases with complete course of treatment and complete treatment, including 30 cases in the treatment group and 29 cases in the control group. Treatment group: Yujin Fang Kanglaite injection, Yujin Fang Lianfu, Kanglaite injection, continuous intravenous drip treatment for 14 days, rest for 2 weeks, 28 days as a cycle; Control group: Kanglaite injection, continuous intravenous drip treatment for 14 days, rest for 2 weeks, 28 days as a cycle, the treatment group were treated for three consecutive cycles. To observe and compare the short-term curative effect and the change of CEA, ECOG, syndrome score before and after treatment in the two groups. Results: 1. The disease control rate of the treatment group and the control group were 86.67 and 65.52, respectively. The comparison between the two groups had statistical significance, indicating that the treatment group was better than the control group. There was a significant difference between the two groups in the expression of tumor marker CEA before and after treatment (p0.05). There was a significant difference in the expression of tumor marker CEA between the two groups (p 0.05), which indicated that the treatment group was better than the control group (P < 0.05). There was a significant difference in ECOG score between the two groups before and after treatment (p0.05), and between the two groups after treatment, there was a significant difference in ECOG score (p0.05), which indicated that the treatment group was better than the control group (4. 05%). There was a significant difference between the two groups before and after treatment, with statistical significance. There was significant difference in TCM symptom score between the two groups (p0.05), which indicated that the treatment group was superior to the control group. Conclusion 1. Yujin prescription can effectively improve the disease control rate; 2. Yujin prescription could significantly reduce the level of tumor marker CEA. Yujin prescription can significantly improve the physical condition, reduce the ECOG score; 4. Yujin prescription can significantly improve clinical symptoms and reduce TCM symptom score.
【学位授予单位】：黑龙江中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R734.2

【参考文献】

中国期刊全文数据库 前10条

1 于涛;张秋生;齐拥军;;康莱特对晚期肺癌患者症状及生活质量的改善作用[J];中国药业;2015年23期

2 马玲;尹蕾;王兵;赵欣;付雪艳;;茯苓研究进展[J];亚太传统医药;2015年12期

3 刘建民;涂强;;青老年肺癌患者临床特点对比研究[J];实用癌症杂志;2015年06期

4 刘俊莉;李瑞霞;郭治;张敏;靳毅;宋新霞;;榄香烯联合NP方案综合治疗晚期非小细胞肺癌的临床观察[J];实用癌症杂志;2015年02期

5 张玄薇;王孝勋;梁臣艳;潘玉丽;庞紫连;;对叶百部化学成分及药理作用研究进展[J];亚太传统医药;2015年03期

6 潘博;潘敏求;黎月恒;李东芳;李琳霈;;养阴清解法则辨证治疗中晚期原发性非小细胞肺癌的临床和实验研究[J];中国医药指南;2014年28期

7 孟晓;韩燕;徐咏梅;张青;富琦;赵文硕;王笑民;杨国旺;;180例晚期非小细胞肺癌患者中医证候分布与组合规律[J];中华中医药杂志;2014年09期

8 仝自强;;肺癌放射治疗的研究进展[J];中国卫生产业;2014年24期

9 高磊;徐涛;孙素芹;;参芪抗瘤方治疗中晚期非小细胞肺癌的临床探讨[J];中外医疗;2014年23期

10 姚晓军;刘伦旭;;肺癌的流行病学及治疗现状[J];现代肿瘤医学;2014年08期

中国博士学位论文全文数据库 前1条

1 刘雨桃;吉非替尼治疗晚期非小细胞肺癌的疗效与生存分析[D];北京协和医学院;2012年

中国硕士学位论文全文数据库 前5条

1 蔡陈浩;扶正抗癌方对TKIs治疗EGFR非突变晚期NSCLC的增敏作用研究[D];广州中医药大学;2015年

2 朱美昌;沙参麦冬汤加减联合化疗治疗晚期非小细胞肺癌的临床观察[D];湖北中医药大学;2013年

3 刘为易;黄金昶教授中医治疗非小细胞肺癌经验总结[D];北京中医药大学;2013年

4 杨昌卫;扶正抗癌方联合吉非替尼治疗晚期非小细胞肺癌的临床研究[D];广州中医药大学;2011年

5 高海利;健脾益肾法治疗中晚期非小细胞肺癌的临床观察[D];广州中医药大学;2008年

，

本文编号：2344039